University of Missouri Research Reactor Files to Start U.S. Production of Medical Isotopes
News | Radiopharmaceuticals and Tracers | April 13, 2017

The University of Missouri Research Reactor (MURR) and its partners Nordion and General Atomics (GA), announced in...

IBA Molecular and Mallinckrodt Nuclear Medicine Merge to Become Curium
News | Radiopharmaceuticals and Tracers | April 11, 2017

IBA Molecular announced that it has merged with previous acquisition Mallinckrodt Nuclear Medicine LLC to form the...

PET
Feature | Imaging | April 11, 2017 | By Greg Freiherr
FDG-PET, cell mutations, lung cancer patients, non-small cell lung cancer, NSCLC, Journal of Nuclear Medicine study

From left to right are patients with EGFR mutation, KRAS mutation, and EGFR– and KRAS– tumors, respectively. Stage I and III tumors are shown in the top and bottom rows, respectively. Arrows indicate the locations of the lung tumors. Credit: Stephen S.F. Yip, Ph.D., and Hugo Aerts, Ph.D., Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School, Boston; John Kim, M.D., University of Michigan Health System, Ann Arbor, Mich.

News | PET Imaging | April 05, 2017

Researchers have used positron emission tomography (PET) to successfully identify genetic cell mutations that can...

GE Healthcare, HealthTrust, supply agreement, nuclear imaging, radiopharmaceuticals
News | Radiopharmaceuticals and Tracers | April 05, 2017

GE Healthcare has signed an agreement with HealthTrust, a group purchasing organization headquartered in Nashville,...

Gamma Medica, LumaGEM molecular breast imaging system, MBI, Mercy Medical Center, Long Island, first New York install
News | Breast Imaging | April 04, 2017

Gamma Medica announced in late March that Mercy Medical Center, a member of Catholic Health Services of Long Island...

Northwestern Memorial Hospital, MR-PET scanner, first in Illinois, Siemens Biograph mMR
News | PET-MRI | March 31, 2017

Northwestern Memorial Hospital is now home to the Chicago area's first combined magnetic resonance (MRI) and...

News | Radiopharmaceuticals and Tracers | March 29, 2017

Advanced Accelerator Applications S.A. announced that its product NETSPOT (gallium Ga-68 dotatate) has been included...

PET/CT, recurrent prostate cancer, fluciclovine F-18, Emory University

CTVPOST (red) = CTVPRE (yellow) union CTVPET (pink). Also shown (upper right corner) are the PRE (square) vs POST (triangle) dose volume histograms for PTV1, PTV2, rectum, bladder, and penile bulb, showing minimal impact on target coverage or organs at risk dose with the modified targets. Image courtesy of Ashesh B. Jani, M.D., and David Schuster, M.D., Emory University.

News | Radiopharmaceuticals and Tracers | March 16, 2017

The featured clinical investigation article of the March 2017 issue of the Journal of Nuclear Medicine demonstrates...

FDG PET/CT, lung cancer, radiation therapy, AJR study, American Journal of Roentgenology
News | Lung Cancer | March 13, 2017

FDG positron emission tomography/computed tomography (PET/CT) is a valuable imaging tool for treatment assessment of...

Nuclear cardiology, nuclear imaging, radiotracer production, automated radiosynthesis module, myocardial perfusion imaging
Feature | Radiopharmaceuticals and Tracers | March 10, 2017 | Anamika Kumari

Huge portions of the globally produced radiotracers find their origin within geographically centralized, commercial...

X0000_Piramal_Neuraceq PET agent_beta amyloid plaque imaging.jpg
News | Radiopharmaceuticals and Tracers | March 09, 2017

March 9, 2017 — Piramal Imaging SA and Isologic Innovative Radiopharmaceuticals recently announced that Health...

Navidea, Lymphoseek, North American rights, sale, Cardinal Health
News | Radiopharmaceuticals and Tracers | March 08, 2017

Navidea Biopharmaceuticals announced the completion of the sale of its Lymphoseek product to Cardinal Health....

PET imaging, atherosclerotic plaque, inflammation, Ga-68-pentixafor, Technishe Universitat Munchen, Germany

Note the high uptake of Ga-68-pentixafor on multi-planar reconstructions in the organs expressing CXCR4 such as the spleen (red arrows) and adrenal glands (yellow arrows), which was nearly completely blocked by the pre-injection of AMD 3100, a potent CXCR4 inhibitor. Strong accumulation of Ga-68-pentixafor was also found in the kidneys (asterisks) reflecting the renal clearance of the tracer. In addition, high, focal activities were detected in the abdominal aorta (red arrowheads) and right carotid artery (orange arrowheads) of atherosclerotic rabbits, whereas no significant signal could be detected in the non-injured left carotid artery (white arrowheads) of atherosclerotic and control rabbits, as well as in the abdominal aorta and right carotid artery of control rabbits. Furthermore, focal activities detected with PET in atherosclerotic plaques of the abdominal aorta and the right carotid artery decreased significantly when the same rabbit was re-imaged after blocking CXCR4 receptors. Image courtesy of Fabien Hyafil, M.D., Ph.D., Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany

News | PET Imaging | March 03, 2017

March 3, 2017 — In the featured article of the March 2017 issue of...

Gamma Medica, European breast imaging market, LumaGem MBI, molecular breast imaging, Hospital Services Limited
News | Molecular Imaging | March 02, 2017

Gamma Medica announced it has partnered with Hospital Services Limited (HSL), a Dublin, Ireland-based established ...

Figure 1: Digital/synthetic reference object (DRO) analysis of the medical imaging market.

Feature | Imaging | March 02, 2017 | By Infinium Global Research

The emerging markets of Asia-Pacific and Latin America will drive the medical imaging market by more than 5 percent...

brain SPECT imaging, dementia, depression, Daniel G. Amen

Representative brain SPECT scans in a patient with Alzheimer's dementia showing substantially reduced brain blood flow in the temporal and parietal lobes compared to a person with depression with mild decreased frontal lobe blood flow. Image courtesy of Amen Clinics.

News | SPECT Imaging | February 22, 2017

February 22, 2017 — Does a patient have depression or a cognitive disorder (CD) such as Alzheimer's disease or both...

News | Radiopharmaceuticals and Tracers | February 16, 2017

Cerveau Technologies Inc. announced it has signed an agreement with Siemens’ PETNET Solutions Inc. that grants the...

Blue Earth Diagnostics, Axumin, fluciclovine F-18, recurrent prostate cancer, Simens PETNET Solutions, increased patient access
News | Radiopharmaceuticals and Tracers | February 07, 2017

Blue Earth Diagnostics and Siemens’ PETNET Solutions announced that an increasing number of radiopharmacies will...

radiotargeted therapy, SST2 antagonists, combat cancer, neuroendocrine tumors, NETs, Journal of Nuclear Medicine study

Comparative receptor autoradiography in various cancer types (A = HE staining) with I-125-JR11 (B+C) and I-125-Tyr3-octreotide (D+E). B and D are the respective total binding, C and E the respective non-specific binding. Bars = 1 mm.

I: Breast cancer. II: Renal cell cancer. III: Medullary thyroid cancer. IV: Non-Hodgkin lymphoma. V: Colon cancer. In cancers I-V, the sections were incubated with 30’000 cpm/100 μl of antagonist or agonist. Cancers I-IV show a much higher density of sst2 with the antagonist. The colon cancer V is negative. VI: Ileal NET, incubated with 10’000 cpm/100 μl of antagonist or agonist. Credit: Jean Claude Reubi, Institute of Pathology, University of Berne, Berne, Switzerland. 

News | Radiation Therapy | February 06, 2017

A study published in the February issue of The Journal of Nuclear Medicine demonstrates the potential of extending...

Overlay Init